Relief Therapeutics Holding (MUN:V6M1) - Hisse Senedi Fiyatı, Haberler ve Analizler

V6M1 Stoklara Genel Bakış

A biopharmaceutical company, focuses on identification, development, and commercialization of novel, patent protected products for the treatment of rare metabolic, dermatological, and pulmonary diseases in Switzerland, Europe, North America, and internationally. Daha fazla detay

V6M1 temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	3/6
Temettüler	0/6

Risk Analizi

Kazançlar son 5 yılda yılda 64.2% oranında azaldı

1 yıldan az nakit akışı var

Hisse senetleri oldukça likit değildir

Anlamlı bir piyasa değeri yok ( €20M )

+ 1 daha fazla risk

Relief Therapeutics Holding SA Rakipler

2invest

XTRA:2INV

€62.7m

Medigene

XTRA:MDG1

€22.5m

co.don

XTRA:CNW

€6.5m

Heidelberg Pharma

XTRA:HPHA

€102.1m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Relief Therapeutics Holding
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	CHF 2.11
52 Haftanın En Yüksek Seviyesi	CHF 10.78
52 Haftanın En Düşük Seviyesi	CHF 2.11
Beta	-14.36
11 Aylık Değişim	0%
3 Aylık Değişim	0%
1 Yıllık Değişim	-80.47%
33 Yıllık Değişim	n/a
5 Yıllık Değişim	n/a
Halka arzdan bu yana değişim	-88.63%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	V6M1	DE Biotechs	DE Pazar
7D	0%	-0.2%	0.8%
1Y	-80.5%	-16.9%	9.1%

Getiri vs. Endüstri: V6M1 geçen yıl % -16.9 oranında getiri sağlayan German Biotechs sektörünün gerisinde kaldı.

Getiri vs Piyasa: V6M1 geçen yıl % 9.1 oranında getiri sağlayan German Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is V6M1's price volatile compared to industry and market?
V6M1 volatility
V6M1 Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.5%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.8%
10% least volatile stocks in DE Market	2.4%

İstikrarlı Hisse Senedi Fiyatı: V6M1 son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: V6M1 'un son bir yıldaki oynaklık değişimini belirlemek için Yetersiz veri.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2013	69	Michelle Lock	www.relieftherapeutics.com

Relief Therapeutics Holding SA Temel Bilgiler Özeti

Relief Therapeutics Holding'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
V6M1 temel i̇stati̇sti̇kler
Piyasa değeri	€21.04m
Kazançlar(TTM)	-€84.73m
Gelir(TTM)	€6.15m

3.4x

P/S Oranı

-0.2x

F/K Oranı

V6M1 aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
V6M1 gelir tablosu (TTM)
Gelir	CHF 5.86m
Gelir Maliyeti	CHF 1.45m
Brüt Kâr	CHF 4.41m
Diğer Giderler	CHF 85.20m
Kazançlar	-CHF 80.79m

Son Raporlanan Kazançlar

Jun 30, 2023

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-6.44
Brüt Marj	75.26%
Net Kâr Marjı	-1,378.18%
Borç/Özkaynak Oranı	1.8%

V6M1 uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

V6M1 Stoklara Genel Bakış

Risk Analizi

Relief Therapeutics Holding SA Rakipler

XTRA:2INV

€62.7m

XTRA:MDG1

€22.5m

XTRA:CNW

€6.5m

XTRA:HPHA

€102.1m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Relief Therapeutics Announces Positive Final Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa

Renexxion, LLC signed a letter of intent to acquire Relief Therapeutics Holding SA (SWX:RLF) in a reverse merger transaction valued at $260 million.

Relief Therapeutics Reports New Study Results for RLF-OD032 and Files Provisional Patents

Relief Therapeutics Holding SA Announces Promising Preliminary Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa

Relief Therapeutics Holding SA Reports Positive Results from RLF-OD032 Proof-of-Concept Clinical Study for Phenylketonuria

Relief Therapeutics Completes Clinical Phase in RLF-OD032 Proof-Of-Concept Study; Topline Results Expected in October 2024

Recent updates

Relief Therapeutics Announces Positive Final Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa

Renexxion, LLC signed a letter of intent to acquire Relief Therapeutics Holding SA (SWX:RLF) in a reverse merger transaction valued at $260 million.

Relief Therapeutics Reports New Study Results for RLF-OD032 and Files Provisional Patents

Relief Therapeutics Holding SA Announces Promising Preliminary Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa

Relief Therapeutics Holding SA Reports Positive Results from RLF-OD032 Proof-of-Concept Clinical Study for Phenylketonuria

Relief Therapeutics Completes Clinical Phase in RLF-OD032 Proof-Of-Concept Study; Topline Results Expected in October 2024

Relief Therapeutics Holding SA Announces PKU GOLIKE Study Results Presentation at SSIEM 2024

Relief Therapeutics Holding SA to Report First Half, 2024 Results on Aug 30, 2024

Relief Therapeutics Holding Announces Michelle Lock Will Not Stand for Re-Election as A Member of the Board of Directors

Relief Therapeutics Holding SA, Annual General Meeting, Jun 27, 2024

Relief Therapeutics Announces Executive Changes

Relief Therapeutics Holding SA announced that it expects to receive CHF 50 million in funding from Global Emerging Markets and another investor

Relief Therapeutics Holding Sa Announces CEO Changes

Relief Therapeutics Holding AG announced that it expects to receive CHF 5 million in funding

Relief Therapeutics Holding AG, Annual General Meeting, Jun 20, 2023

Relief Therapeutics Announces Enrollment of First Three Patients in Proof-Of-Concept Clinical Trial of Rlf-Td011 for the Treatment of Epidermolysis Bullosa

RELIEF THERAPEUTICS Holding SA Announces IRB Approval of Investigator-Initiated Trial Evaluating RLF-TD011 as an Adjunctive Treatment for Cutaneous T-Cell Lymphom

Acer Therapeutics and Relief Therapeutics Announce U.S. FDA Approval of Olpruva™ for Patients with Urea Cycle Disorders

Relief Therapeutics Holding AG (SWX:RLF) acquired ZYESAMI of NRx Pharmaceuticals, Inc.

Relief Therapeutics Holding AG and NRx Pharmaceuticals, Inc. Announces Close of Definitive Settlement Agreements

Relief Therapeutics Holding AG Appoints Jeremy Meinen as Chief Financial Officer

Relief Therapeutics Holding AG Announces Six-Month Stability Data on a New Formulation of RLF-100 (Aviptadil)

RELIEF THERAPEUTICS Holding SA Promotes Paolo Galfetti to Chief Operating Officer

Relief Therapeutics Holding SA Announces U.S. Launch of PKU GOLIKE

Relief Therapeutics Holding AG Announces IRB Approval and Initiation of an Investigator Initiated Trial of Nexodyn for Epidermolysis Bullosa At Ann & Robert H. Lurie Children's Hospital of Chicago

Relief Therapeutics Holding AG has filed an IPO.

Relief Therapeutics Holding AG and NRx Pharmaceuticals, Inc. Announce Tentative Settlement of Pending Litigation

Relief Therapeutics Holding SA Appoints David McCullough as Head of U.S. Market Access, Effective August 22, 2022

RELIEF THERAPEUTICS Holding SA and Acer Therapeutics Inc. Announce That the European Commission Has Granted Orphan Drug Designation for Acer-001 in Maple Syrup Urine Disease

Relief Therapeutics Holding Ag Announces U.S. Food and Drug Administration Accepts for Review Acer’s Resubmitted New Drug Application

Acer Therapeutics and Relief Therapeutics Announce FDA Acceptance for Review of NDA Resubmission for ACER-001 for Treatment of UCDs

Relief Therapeutics Appoints Serene Forte, Ph.D., MPH, as Senior Vice President, Head of Genetic Medicine

Acer Therapeutics and Relief Therapeutics Announce Update on U.S. FDA Review of New Drug Application for ACER-001

Relief Therapeutics Expands U.S. Commercial Team

Acer Therapeutics Inc. and Relief Therapeutics Holding AG Announce Presentation of Acer-001 Data At the Genetic Metabolic Dieticians International Conference

Relief Therapeutics Holding AG, Annual General Meeting, May 31, 2022